DaVita Inc. with ticker code (DVA) now have 9 analysts in total covering the stock. The consensus rating is pointing to ‘none’. The target price High/Low ranges between $186.00 and $134.00 suggesting an average analyst share price target price of $156.90. (at the time of writing). Now with the previous closing price of $164.14 this now indicates there is a potential downside of -4.4%. Also worth taking note is the 50 day moving average now sits at $158.31 and the 200 day MA is $143.32. The market cap for the company is 13.58B. Currently the stock stands at: $165.51 USD
The potential market cap would be $12,977,164,876 based on the market consensus.
The company has a dividend yield of 3.8%. Other points of data to note are a P/E ratio of 17.82, revenue per share of $145.29 and a 6.94% return on assets.
DaVita Inc. is a healthcare provider. The Company provides kidney care services in the United States. The Company’s operations are comprised of its U.S. dialysis and related lab services business (its U.S. dialysis business), its U.S. integrated kidney care business, its U.S. other ancillary services and its international operations (its ancillary services). The U.S. dialysis and related lab services (U.S. dialysis) business treats patients with chronic kidney failure, and end-stage kidney disease (ESKD). Its services include outpatient hemodialysis services, hospital inpatient hemodialysis services, and home-based dialysis services. The ancillary services consist of integrated kidney care services, physician services, clinical research programs, and transplant software business, as well as international operations. The Company operates approximately 2,724 outpatient dialysis centers in the United States.
